Pharmacological inhibition of NFAT rescues ASNase-induced immune responses. (A) Schematic representation of ASNase immunization, 11R-VIVIT treatment, and the ASNase challenge protocol. (B) Immunized WT mice treated with 11R-VIVIT (10 mg/kg) are protected against developing hypothermia when challenged with ASNase. (C-D) 11R-VIVIT–treated mice have lower levels of IL-4 plasma levels and CD4⁺IL-4⁺ T-cell frequency. (E-J) Furthermore, 11R-VIVIT–treated mice had lower plasma mMCP-1 (E), higher ASNase drug levels (F), fewer detectable ASNase ICs (G), and lower anti-ASNase IgG/IgE and total IgE levels relative to controls (H-J). *P < .05; **P < .01; ****P < .0001.